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INTRODUCTION
Arginases catalyze the hydrolysis of L-arginine to form L-ornithine and urea. The urea cycle arginase, arginase I (or liver arginase), is cytosolic, while arginase II (or kidney arginase) is located in mitochondria. Arginase activity has been detected in non-hepatic tissues that lack a complete urea cycle including alveolar macrophages (1, 2, 3) , and fibroblasts (4) . In alveolar macrophages arginase I appears to be the major contributor to total arginase activity, although both isoenzymes were expressed in this cell type (3) . Ornithine, the product of arginase catalytic activity is the precursor of proline and polyamines, which have multiple effects on connective tissue, smooth muscle, and mucus producing cells (5) (6) (7) (8) (9) .
Interest in arginases is growing because of their potential for affecting the availability of Larginine for nitric oxide synthases (NOSs). For instance, it was shown that arginase can limit the availability of L-arginine for NO synthesis in macrophages (10, 11) . The potential relevance of competition between arginases and NOS for their common substrate for airway physiology was demonstrated by Meurs and coworkers (12, 13) . They showed that limitation of L-arginine bioavailability for NO synthesis from constitutive NOS by arginase contributed to airway hyperreactivity in naïve guinea-pigs (12) . In addition, bronchial hyperresponsiveness could be normalized by pharmacological inhibition of arginase in a guinea-pig model of asthma (13) . The relevance of increased arginase activity and reduced L-arginine bioavailability in human asthma has recently been demonstrated (14) (15) (16) (17) .
Airways disease in cystic fibrosis (CF) is characterized by chronic inflammation, chronic bacterial infection and recurrent infection-associated pulmonary exacerbations (18) (19) (20) (21) (22) (23) . These 3 neutrophil-dominated exacerbations are accompanied by significant deterioration in pulmonary function and a rise in inflammatory markers in the airways (24, 25) . Of interest, expression of the inducible isoform of NOS, NOS2, is not increased but decreased or even absent in CF airways (26, 27) . The mechanisms resulting in NOS2 deficiency in CF are poorly understood, but limited evidence suggest that decreased NOS2 expression is related to CF airway inflammation (28) .
There is recent evidence suggesting that expression of inducible NOS (NOS2) can be downregulated by limitation of extracellular L-arginine concentrations, reduction of cellular arginine uptake capacity, or over-expression of arginase (29) (30) (31) (32) .
The potential role of arginase for CF airway inflammation and NO synthesis has not been studied. We therefore measured arginase activity in sputum of stable CF patients and patients with a pulmonary exacerbation before and after i.v. antibiotic treatment. Parts of this work have been published previously in abstract form (33, 34) .
MATERIALS AND METHODS (656 words)

Study design
CF patients that were seen in the outpatient department or admitted for i.v. antibiotic treatment between June 2003 and September 2004 were eligible for this study if they could spontaneously expectorate sputum. The diagnosis of CF in all participating patients had been confirmed by repeated sweat tests with chloride concentrations exceeding 60 mmol/L and by mutation analysis of the CFTR gene.
Sputum was collected for the measurement of arginase activity at admission and after 14 days of i.v. antibiotic therapy. Sputum from admitted patients was compared to sputum from clinically stable CF patients presenting to the CF clinic without signs of acute upper airway infection or pulmonary exacerbation for the last six weeks. Arginase activity in CF sputum was also compared to that of induced sputum from healthy controls, who had to be nonsmokers with no history of asthma or atopy. After pre-treatment with a short acting beta-2 agonist, 4% saline was administered by nebulizer (Pari Master, Pari GMBH, Starnberg, Germany) for up to 20 min while subjects were encouraged to cough and expectorate sputum into a sterile container.
Written informed consent was obtained from each CF patient, and/or their parents, and all healthy controls, respectively. The study was approved by the institutional review board of the University of Essen.
Study population
66 CF patients (31 female and 35 male) with a mean (SEM) age of 20.5 (7.2) years were included in this study. Mean (SEM) FEV1 was 49.5 (24.2) %, and FVC was 66.3 (23.2) % of predicted reference values. Forty patients were homozygous and 13 patients were compound 5 heterozygous for the F508 CFTR mutation ( F508 allele frequency 70.5%). Fifty-four of the patients studied (81.8%) had airway cultures positive for P. aeruginosa.
Of the 47 patients that were admitted to hospital for i.v. antibiotic treatment, 10 received oral steroids as part of their regular treatment (Fig. 1) . Of the remaining 37 patients 26 were treated for pulmonary exacerbation while 11 received antibiotics routinely every three months. 19 CF patients that were seen in the out-patient department of the Children's Hospital in Essen were in clinically stable condition. There were no differences between these 3 groups in age, sex and pulmonary function.
CF sputum was compared to induced sputum from 11 healthy controls (5 females) that were 25.6 (3.1) years of age.
Sputum processing
Immediately after expectoration sputum samples were incubated 1:1 in 0.1% Triton X100 containing the protease inhibitors phenylmethylsulfonyl fluoride (PMSF, 1 mM), leupeptin 0.5 µg/ml, pepstatin A 0.7 mg/ml and EDTA 2 mM. Mixed samples were vortexed for homogenization. All sputum lysate samples were stored at -70°C until analyzed.
Arginase activity assay
Sputum samples were mixed with DTT (final concentration of 5 mM), appropriately diluted and analyzed for arginase activity as described previously (4), based on spectrophotometric determination of urea after the addition of L-arginine (3, 35) . Arginase activity was expressed as Units/mg protein (one unit is the enzyme activity catalyzing the formation of 1 µmol urea/min).
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Additional details on the specificity and methodology of the arginase assay are provided in an online data supplement.
NO measurement
A chemiluminescence analyzer (NOA 280, Sievers, Boulder, CO, USA) was used to measure FENO. Single breath on-line measurements for the assessment of lower airway NO were performed at a constant expiratory flow of 50 ml x min-1, (FeNO50) in accordance with published ERS/ATS standards (37, 38) . The NO analyzer was calibrated before each study with 0 and 185-ppb NO calibration gas (Linde AG, Unterschleissheim, Germany). The mean value of three endexpiratory NO concentrations within a variation of 15% was calculated for each subject.
Statistics
Data were expressed as mean ± standard error of the mean (SEM). Kolmogorov-Smirnov test revealed that values for arginase activity were not normally distributed in the groups.
Comparisons between groups were therefore made by Wilcoxon test. Intra-group comparison was done by paired Wilcoxon test. A p value below 0.05 was considered statistically significant. PC-Statistik v2.11 (TopSoft Hannover, Germany) was used for statistical analysis.
RESULTS
High levels of arginase activity were found in all CF sputum samples. The specificity of the arginase activity was confirmed by showing complete inhibition by the specific arginase inhibitor N N -hydroxy-nor-L-arginine (nor-NOHA) in a subset of samples (38) . Interference of the assay by urease could be excluded (see web based data supplement). In the admitted patients, arginase activity before antibiotic therapy was significantly lower in those treated with systemic steroids (n=10) compared to non-steroid treated patients (n=37) (0.321 ± 0.071 vs. 0.853 ± 0.118 U/mg protein, p=0.025). Therefore, the subsequent analysis was limited to CF patients not receiving systemic corticosteroid therapy. In non-steroid treated patients admitted for i.v.
antibiotic treatment, sputum arginase activity was significantly higher in patients with exacerbation (n=26) compared to those admitted for routine i.v. treatment (n=11) (1.032 ± 0.148 vs. 0.430 ± 0.122 U/mg protein, p=0.007). Sputum arginase activity from clinically stable CF patients (0.370 ± 0.091 U/mg protein) did not differ from arginase activity in patients admitted for elective clean-out but was significantly lower than in patients admitted for exacerbation (p<0.004, Wilcoxon test) ( Figure 2 ).
Mean sputum arginase activity decreased significantly in both groups after i.v. antibiotic treatment, but the decline was much more pronounced in patients with pulmonary exacerbations (Table 1, Figure 2 ). No statistically significant difference in arginase activity was found between sputum from CF patients treated for exacerbation or for elective clean-out after 14 days of i.v.
antibiotic therapy. Arginase activity after treatment was also not different from baseline values in clinically stable CF patients. However, arginase activity in sputum was still significantly higher in all CF groups when compared to induced sputum from 11 healthy controls ( Figure 2 ).
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We then tested for a possible relationship between sputum arginase activity and pulmonary function in CF. Since sputum was not available from 7 patients and pulmonary function tests were not performed by two patients, complete this analysis was performed in 57/66 patients that were either admitted to hospital for i.v. antibiotic treatment or were seen in the out-patient department in clinically stable condition. In these patients a negative correlation was seen between sputum arginase activity and FEV1 (r = -0.38, p = 0.003). This correlation was also seen in the subgroup of 35 patients that were admitted for i. Indirect evidence for increased arginase activity in CF was provided by a recent study assessing the effect of a single dose of oral L-arginine on amino acid concentrations in plasma. The increase in ornithine, a product of arginase activity, was significantly higher in CF than healthy controls while the increase in FeNO was significantly higher in the controls (39) . Ornithine is the precursor of proline and the polyamines (e.g., putrescine, spermidine, and spermine), which promote collagen production and cell proliferation (40) (41) (42) (43) (44) . Arginase activity may therefore have direct effects on fibrosis and airway remodeling in CF. Of interest, polyamine plasma levels have been reported to be increased in CF in an age-dependent manner (45).
Our observations suggest that arginase is a marker of inflammation in CF as we observed the highest activity levels during pulmonary exacerbation, a significant decrease with antibiotic treatment, and elevated activity even in clinically stable patients who are known to have ongoing airway inflammation. This notion is also supported by the fact that arginase activity was lower in patients treated with steroids compared to those untreated, although the number of patients treated with systemic steroids was low. While different cell types have the capability to express arginase, arginase has recently been shown to be constitutively expressed in azurophil granules of human neutrophils (46) , the main inflammatory cell in CF airways. High arginase activity in CF sputum may therefore reflect neutrophil airway inflammation in this condition. Interestingly, arginase activity in neutrophils was found not to be inducible by a variety of proinflammatory stimuli (46) . Therefore, increased arginase activity during pulmonary exacerbation may simply reflect an increased neutrophilic burden. Alternatively, other cell types from the airways such as epithelial cells, macrophages and fibroblasts may also contribute to total airway arginase.
There is an increasing body of evidence that arginases may contribute to bronchomotor control in asthma by interference with NO synthesis (12, 13, 47, 48) . In animal experiments with isolated perfused tracheae from naïve guinea pigs the inhibition of arginase with specific inhibitors 11 caused a concentration-dependent decrease in methacholine-induced airway constriction. This effect of arginase inhibition could be reversed by the NOS-inhibitor L-NAME (12) . Effects of an imbalance of this system induced by inflammation, was demonstrated in a subsequent study by the same group (13) . In a guinea pig model of allergic asthma, incubation with the NOS-inhibitor L-NAME in unchallenged control animal tracheae resulted in hyperresponsiveness similar to that observed in allergen-challenged animals. Addition of the arginase inhibitor nor-NOHA normalized the hyperresponsiveness of challenged airways to basal controls. This effect was fully reversible by L-NAME. Arginase activity in the hyperresponsive airways was significantly increased (13) . Electrical field stimulation (EFS)-induced relaxation in guinea pig tracheas precontracted with histamine was significantly reduced with the NOS inhibitor L-NNA, while the arginase inhibitor nor-NOHA increased EFS-induced relaxation similar to L-arginine (49) .
Similar experiments in CF-animal models have, to our knowledge, not been published. However, relaxation of precontracted tracheae to electrical field stimulation and substance P was reduced in cftr -/-mice compared to wild-type animals, but the relaxation defect in CF airway could be reversed by addition of exogenous NO and L-arginine (49) . This study shows that in CF the relative absence of NO compromises airways relaxation, and contributes to bronchial obstruction. In CF patients we observed that FEV1 was negatively correlated with sputum arginase activity, suggesting that patients with more pronounced airway obstruction have higher arginase activity in their airways than patients with better pulmonary function. In addition, arginase activity significantly decreased during antibiotic treatment in CF. Positive correlations were found between arginase activity before antibiotic treatment and improvement in pulmonary function during the 14 days of antibiotic treatment. These findings may suggest that high 12 arginase activity, possibly by substrate competition, contributes to NO deficiency and thereby to airway obstruction in CF patients.
To date, at least four mechanisms have been proposed to explain low FeNO in patients with CF; 1) reduced formation of NO due to a lack of inducible NOS (NOS2) expression in airway epithelium (26, 27) , 2) conversion of NO to metabolites such as peroxynitrite by, for instance, neutrophil derived superoxide (50), 3) consumption of NO by denitrifying bacteria (51), and 4) mechanical retention of NO in CF mucus (52, 53) . Likely, the relative contribution of distinct mechanisms to low FeNO differs between patients and may also change with disease activity in an individual patient. The present study suggests that increased arginase activity may also have an effect on NO formation (and NO-mediated processes) in the CF airways. This regulatory effect of arginases on NO formation may not be confined to the simple concept of substrate limitation for NO synthesis, as it has been demonstrated that the expression of NOS2 is inhibited when arginine availability is reduced. This was shown for limitation of extracellular L-arginine concentrations, reduction of cellular arginine uptake capacity, and over-expression of arginase (29) (30) (31) (32) . In these studies, translation of NOS2 mRNA was inhibited by low concentrations of Larginine (29, 30) . There may be multiple mechanisms by which L-arginine mediates NOS2 expression, such as control of NOS protein stability or induction of NOS2 mRNA, as recently reviewed (54) . NOS2 from airway epithelium is currently thought to be the major contributor to exhaled NO as shown in children with asthma where the level of NOS2 protein in airway cells obtained by BAL correlated with the fraction of exhaled NO (FeNO) (55).
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High arginase activity is expected to have different pathophysiologic consequences depending on whether NO production via NOS2 is up-or downregulated. In asthma, where NOS2 is known to be over expressed in airway epithelium, increased arginase activity is thought to cause depletion of substrate for constitutive NOSs with L-arginine being predominantly transformed into reactive NO metabolites via NOS2 (13) (14) (15) (16) (17) . In contrast, NOS2 is downregulated or lacking in CF airway epithelial cells (26, 27) and substrate deficiency for NOSs is expected to further decrease NO production.
Studies in CF airway cells suggest that decreased NOS2 expression in the airways may be detrimental and contribute to the impaired defense against P. aeruginosa in CF (26) (27) (28) 56) . Of interest, the expression of NOS2 in CF airways was recently shown to correlate with markers of inflammation, suggesting that an increase in inflammation results in a decrease of NOS2 expression (28) . This parallels the observation of a positive correlation between FeNO and pulmonary function reported by us and others (57) (58) (59) . In the current study we observed that arginase activity was negatively correlated to pulmonary function in CF. Taking these observations together, one could speculate that inflammation results in induction of arginase, followed by a decrease of NOS2 expression and consequently in low FeNO (and worsening of pulmonary function, as discussed above). The observation that antibiotic treatment for pulmonary function results in an increase of FeNO in CF (51,60) supports this theory. In contrast to these previous studies, we did not observe an increase of FeNO with antibiotic treatment.
However, changes of FeNO may not adequately reflect NO production by airway cells in patients with large amounts of airway secretions as it is the case during an acute exacerbation.
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Arginases are not only expressed in human cells but also by bacteria, such as P. aeruginosa and Staph. aureus. A contribution of bacterial arginase to total sputum arginase activity can, therefore, not be excluded. Of interest, it has recently been shown for H. pylori that spermine, which is synthesized from the arginase product L-ornithine, significantly attenuated NOS2 protein translation and NO production of macrophages in a concentration-dependent manner.
This observation has been postulated to be a mechanism by which H. pylori persists in the gastric mucosa (61) . Whether similar factors are relevant in CF airways is currently unknown.
In conclusion, our results demonstrate increased arginase activity in CF sputum. Patients with more advanced disease as well as patients with a pulmonary exacerbation have higher arginase activity, suggesting that arginase activity is directly related to the degree of airway inflammation.
Increased arginase activity may be of pathophysiologic relevance as it decreases L-arginine availability, the substrate for NO synthesis, thereby contributing to airway obstruction in CF patients. Figure 1 . Description of the CF study population antibiotics for 14 days. Shown are the correlations of arginase activity and FEV1 in these patients before treatment (Fig. 4A) , and the correlation of changes in arginase activity ( arginase) and FEV1 during treatment (Fig. 4B) . O n l i n e D a t a S u p p l e m e n t
FIGURE LEGENDS
MATERIALS AND METHODS
Arginase activity assay
Specific arginase activity was measured similarly as recently described (E1). Samples were thawed, mixed vigorously, centrifuged at 1130 g for 10 min before DTT was added to a final concentration of 5 mM. 500 µl portions of the appropriately diluted supernatant were mixed with 500 µl 25 mM Tris-HCl (pH 7.4) containing 5 mM MnCl 2 and incubated for 10 min at 56°C.
Then 50 µl of a 0.5 M L-arginine solution (pH 9.7) were added to 50 µl of heat-activated sputum lysates and incubated for 1 h at 37°C. In order to remain within the linear range of the assay the sputum samples had to be diluted at least 10-fold, in most cases 30 to 300-fold. The amount of urea was then determined by a spectrophotometric assay based on a reaction withisonitrosopropiophenon (E2,E3). Arginase activity was calculated from a standard curve for urea
(1-30 µg urea) and was expressed in absolute terms as Units/mg protein (one unit is the enzyme activity that catalyzing the formation of 1µmol urea/min). The specificity of the assay was confirmed by showing that the specific arginase inhibitor N ω -hydroxy-nor-L-arginine (nor-NOHA) (E4) inhibited the formation of urea in a concentration and L-arginine-dependent manner (Fig. A) . In additional samples (n = 14) it was confirmed that 3 mM nor-NOHA inhibited the urea formation under the standard assay conditions (presence of 500 mM LArginine) by 90 ± 2%.
Using liver extracts as a source of arginase it was shown that presence of DTT did not affect the linear range of the standard curve for urea, but caused a slight increase in arginase activity, by 19±4% (n=9). Likewise, presence of the protease inhibitor cocktail (phenylmethylsulfonyl fluoride (PMSF, 1 mM), leupeptin 0.5 µg/ml and pepstatin A 0.7 mg/ml) did not affect the standard curve for urea, but resulted in higher arginase activity (2.7±0.15 vs. 1.87±0.28 U/mg protein), most like by preventing the proteolytic loss of enzyme activity.
Since urease activity is known to be present in saliva (E5), urease activity in sputum sample could interfere with the arginase assay, which is based on the formation of urea. Indeed, when undiluted samples of saliva or sputum, spiked with 15 µg urea were incubated under arginase assay conditions the recovery of urea was 59±2% and 76±8%, respectively (each n=7), indicating significant urease activity. In saliva and sputum samples diluted 1:3 the recovery was 81±1% and 86±5%, respectively, and in samples diluted 1:10 or higher no significant loss of urea was observed. Since for determination of arginase activity samples were diluted at least 10-fold, disturbance of the assay by urease can be excluded. We also compared arginase activity in spontaneously expectorated sputum, induced sputum and saliva in 8 CF patients. No significant differences were found between induced and spontaneously expectorated sputum (median 0.56 vs. 0.53 U/mg protein), whereas saliva concentrations were 30 times lower (0.015U/mg protein, p< 0.001, Wilcoxon test). Arginase activity is expressed as percent of the respective value in absence of nor-NOHA (Mean ± SEM of n = 4-5). 
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